B O O K - American College of Rheumatology

More documents

Recommendations

Info

ACR Poster Session A 559. Week 12 Response Is a Better Predictor Than Baseline Disease Characteristics of Long-Term Remission in Ankylosing Spondylitis. Joachim Sieper 3 , Desiree van der Heijde 4 , Steve Brown 2 , Frederic Lavie 1 and Aileen Pangan 2 , 1 Abbott Laboratories, Rungis, France, 2 Abbott Laboratories, Abbott Park, IL, 3 Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Leiden University Medical Center, Leiden, The Netherlands. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I 560. A Multi-Center, Open-Label, Proof of Concept Study of Imatinib Mesylate Demonstrates No Benefit for the Treatment of Fibrosis in Patients with Early, Diffuse Systemic Sclerosis. Oliver Distler 8 , Jorg H. W. Distler 9 , John Varga 4 , Christopher P. Denton 7 , Robert A. Lafyatis 1 , Fredrick M. Wigley 3 , Georg Schett 2 , Marco Matucci-Cerinic 10 , Timothy M. Wright 5 , Arthur P. Bertolino 6 and Peter Gergely, Jr 6 , 1 Boston University School of Medicine, Arlington, MA, 2 Friedrich Alexander Univ, Erlangen, Germany, 3 Johns Hopkins University, Baltimore, MD, 4 Northwestern Univ Feinberg School, Chicago, IL, 5 Novartis Institutes for Biomedical Research, Cambridge, MA, 6 Novartis Institutes for Biomedical Research, 7 Royal Free Hospital, London, United Kingdom, 8 University Hospital Zurich, Zurich, Switzerland, 9 University of Erlangen, Erlangen, Germany, 10 University of Florence, Firenze, Italy. 561. Baseline Differences in the “Borderline” Pulmonary Hypertension vs. “Normal” Hemodynamics: PHAROS Registry. Dinesh Khanna 4 , Rajeev Saggar 4 , Daniel Furst 4 , Lorinda Chung 3 , James Seibold 5 , Tracy Frech 7 , ELENA Schiopu 6 , Rajan Saggar 4 , Marcy Bolster 2 , Virginia Steen 1 and PHAROS Investigators, 1 Georgetown University, 2 MUSC, 3 Stanford, 4 UCLA, 5 Univ of Connecticut, 6 Univ of Michigan, 7 Univ of Utah. 562. Cigarette Smoking Is Not a Risk Factor for Systemic Sclerosis. Prateek Chaudhary 3 , Xing Chen 6 , Shervin Assassi 3 , Olga Gorlova 7 , Hilda Draeger 5 , Emilio Gonzalez 8 , Terry McNearney 1 , Marilyn Perry 3 , Jason Anderson 4 and Maureen D. Mayes 2 , 1 Indianapolis, IN, 2 University of Texas Health Science Center at Houston, Houston, TX, 3 University of Texas Health Science Center Houston, Houston, TX, 4 University of Texas Health Science Center Houston, 5 University of Texas Health Science Center San Antonio, San Antonio, TX, 6 University of Texas MD Anderson Cancer Center, Houston, TX, 7 University of Texas MD Anderson Health Science Center, Houston, TX, 8 University of Texas Medical Branch at Galveston, Galveston, TX. 563. Clinical Characteristics of Systemic Sclerosis Sine Scleroderma Associated Interstitial Lung Disease. Rohit Aggarwal 3 , Mary Lucas 2 , Noreen Fertig 2 and Thomas A. Medsger 1 , 1 Univ of Pittsburgh, Pittsburgh, PA, 2 University of Pittsburgh, 3 University of Pittsburgh Medical Center, Pittsburgh, PA. 564. Clinical Predictive Factors on Response to Oral Monotherapy in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Yih Chang Lin, Soumya Chatterjee, Meng Xu, Raed Dweik and Joseph Parambil, Cleveland Clinic. 565. Combined Analysis of Outcomes of Sitaxentan Treatment of Pulmonary Arterial Hypertension (PAH) Associated with Systemic Sclerosis (Scleroderma). James R. Seibold 5 , Marco Matucci-Cerinic 6 , Michael Louie 3 , Stephen Watt 3 , Simon A. Teal 4 , Xuexuan Liu 1 , Lie-Ju Hwang 3 and David Langleben 2 , 1 Aerotek, Houston, TX, 2 Cardiology, Montreal Jewish Hospital, Montreal, Canada, 3 Pfizer Inc, New York, NY, 4 Pfizer Ltd, Tadworth, Surrey, UK, 5 Rheumatology, University of Connecticut, Farmington, Farmington, CT, 6 University of Florence, Firenze, Italy. 566. Comparative Analysis of Change in Modified Rodnan Skin Score in Patients with Diffuse Systemic Sclerosis Receiving Imatinib Mesylate Suggests Similar Disease Course to Matched Patients Receiving Standard Therapy. Christopher P. Denton 9 , Svetlana I. Nihtyanova 2 , John Varga 5 , Oliver Distler 10 , Fredrick M. Wigley 4 , Robert A. Lafyatis 1 , Jorg H. W. Distler 11 , Georg Schett 3 , Marco Matucci-Cerinic 12 , Timothy M. Wright 6 , Monica Costa Antunes 8 , Amy Racine 8 , Arthur P. Bertolino 7 and Peter Gergely, Jr 7 , 1 Boston University School of Medicine, Arlington, MA, 2 Center for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 3 Friedrich Alexander Univ, Erlangen, Germany, 4 Johns Hopkins University, Baltimore, MD, 5 Northwestern Univ Feinberg School, Chicago, IL, 6 Novartis Institutes for Biomedical Research, Cambridge, MA, 7 Novartis Institutes for Biomedical Research, 8 Novartis Pharma, 9 Royal Free Hospital, London, United Kingdom, 10 University Hospital Zurich, Zurich, Switzerland, 11 University of Erlangen, Erlangen, Germany, 12 University of Florence, Firenze, Italy. 567. Comparison of Estimated Pulmonary Artery Systolic Pressure by Echocardiography (PASPECHO) and Right Heart Catheterization (PASPRHC) in Patients with Systemic Sclerosis (Scleroderma, SSc). Elena Schiopu 3 , Ann J. Impens 3 , Melvyn Rubenfire 2 , Fazleomar Mahmood 3 and Kristine Phillips 1 , 1 University of Michigan, Ann Arbor, MI, 2 University of Michigan, Division of Cardiology, Ann Arbor, MI, 3 University of Michigan, Scleroderma Program, Ann Arbor, MI. 568. Determination of the Accurate Incidence of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis, Mixed Connective Tissue Disease and Systemic Lupus Erythematosus by Prospective Study for 3-Years. Sumiaki Tanaka 1 , Kenta Hoshi 4 , Junichi Tanaka 4 , Tatsuhiko Wada 4 , Toshimichi Matsui 4 , Tatsuo Nagai 4 , Jun Okada 2 and Shunsei Hirohata 3 , 1 Drexel University College of MedicineDepartment of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, 2 Drexel University College of MedicineDepartment of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 3 Drexel University College of MedicineDepartment of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 4 Drexel University College of MedicineDepartment of Rheumatology and Infectious Diseases, Kitasato University School of Medicine. 569. Difficulty Using World Health Organization Criteria To Categorize Pulmonary Hypertension in Patients with Systemic Sclerosis. Jessica K. Gordon 3 , Mardi Gomberg- Maitland 5 , Barbara M. Segal 2 , Robyn T. Domsic 6 , Ami A. Shah 4 , Laura K. Hummers 4 , Virginia D. Steen 1 , Evelyn Horn 7 and PHAROS Investigators, 1 Georgetown University Medical Center, Washington, DC, 2 Hennepin County Medical Center, Minneapolis, MN, 3 Hospital for Special Surgery, New York, NY, 4 Johns Hopkins University, Baltimore, MD, 5 University of Chicago, 6 University of Pittsburgh, Pittsburgh, PA, 7 Weill-Cornell Medical College. 570. Dyspnea in Scleroderma Patients from the PHAROS Registry: A Major Contributor to Disability. Lorinda Chung 2 , Hubert Chen 3 , Dinesh Khanna 5 , Ann J. Impens 4 , Virginia D. Steen 1 and PHAROS Investigators, 1 Georgetown University Medical Center, Washington, DC, 2 Stanford Univ Medical Center, Palo Alto, CA, 3 UCSF, 4 Univ of Michigan Lobby M 2500, Ann Arbor, MI, 5 University of California Los Angeles, Los Angeles, CA. 186 2010 Program Book
ACR Poster Session A 571. Epidemiology of Systemic Sclerosis in the Afro-Caribbean Population of Martinique, FWI: A Population-Based Study. Christophe Deligny, Vincent Goeb, Marie Elise Truchetet, Valentine Kahn, Veronique Dehlinger, Patrick Numéric, Christian Derancourt, Georges Jean Baptiste and Serge Arfi, CHU de Fort de France, Fort de France, Martinique. 572. European Scleroderma Study Group (ESCSG) Activity Index Is Correlated to Quality of Life Measures Both at Admission and Overtime. Gabriele Valentini 2 , Michele Iudici 3 , Giuseppina Abignano 3 , Serena Vettori 1 and Giovanna Cuomo 3 , 1 Italy, 2 Rheumatology Unit - Second University of Naples, Napoli, Italy, 3 Rheumatology Unit- Second University of Naples, Italy. 573. Evaluation of an Imatinib Response Gene Signature in Patients with Systemic Sclerosis. Lorinda Chung 3 , Pedro Ruiz 5 , Tammara Wood 1 , Stanford Shoor 2 , William Robinson 4 , Michael Whitfield 1 , Howard Chang 5 and David Fiorentino 5 , 1 Dartmouth Medical School, 2 Kaiser Permanente of Northern California, 3 Stanford Univ Medical Center, Palo Alto, CA, 4 Stanford Univ School of Med, Stanford, CA, 5 Stanford University School of Medicine. 574. Evaluation of the Effect of Ambrisentan on Digital Microvascular Flow in Patients with Systemic Sclerosis Using Laser Doppler Perfusion Imaging. Nilanjana Bose 2 , James F. Bena 2 , Charles M. Trunick 3 , Debora J. Bork 2 , Geetha Krishnan 2 , John Petrich 2 and Soumya Chatterjee 1 , 1 Cleveland Clinic, Richmond Heights, OH, 2 Cleveland Clinic, Cleveland, OH, 3 Cleveland Clinic. 575. Identification of New Autoantibody Specificities in Different Subsets of Systemic Sclerosis Patients. Guillaume Bussone 3 , Hanadi Dib 4 , Mathieu C. Tamby 1 , Cédric Broussard 5 , Loïc Guillevin 2 and Luc Mouthon 2 , 1 Université Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR 8104), Paris, France, 2 Universite Paris Descartes, Faculte de Medecine, Pole de Medecine Interne et Centre de Reference Pour les Vascularites Necrosantes et la Sclerodermie Systemique, Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, 3 Universite Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR 8104), Paris, France, 4 Universite Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR 8104), Paris, France, 5 Universite Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR 8104), Plate-forme Proteomique Paris 5 , Paris. 576. Intravenous Immunoglobulin (IVIg) in the Treatment of Systemic Sclerosis (SSc) Associated Myopathy. Arnaud Dzeing- Ella 7 , Alice Bérezné 7 , Brigitte Ranque 4 , François-Jérôme Authier 1 , Yannick Allanore 5 , Jean Cabane 3 , Eric Hachulla 2 , Loïc Guillevin 7 and Luc Mouthon 6 , 1 Service d’Histologie, Hôpital Henri- Mondor, Creteil, France, 2 Service de Medecine Interne, Hôpital Claude-Huriez, Lille, 3 Service de Medecine Interne, Hôpital Saint-Antoine, Paris, France, 4 Service de Medecine Interne, HEGP, Paris, France, 5 Service de Rhumatologie A, Hôpital Cochin, Paris, France, 6 Universite Paris Descartes, Faculte de Medecine, Pole de Medecine Interne et Centre de Reference Pour les Vascularites Necrosantes et la Sclerodermie Systemique, Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, France, 7 Universite Paris Descartes, Faculte de Medecine, Pole de Medecine Interne et Centre de Reference Pour les Vascularites Necrosantes et la Sclerodermie Systemique, Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris. 577. Modeling Smoking in Systemic Sclerosis: A Comparison of Different Statistical Approaches. Marie Hudson 3 , Ernest Lo 2 , Russell Steele 3 and Murray Baron 1 , 1 Jewish General Hospital, Montreal, QC, Canada, 2 Lady Davis Institute, Jewish General Hospital, 3 McGill University. 578. Nailfold Microangiopathy and Pheripheral Blood Perfusion Correlate with Internal Organ Involvement in Sistemic Sclerosis. Alberto Sulli 1 , Carmela Ferrone 2 , Carmen Pizzorni 2 , Elisa Alessandri 2 , Francesca Ravera 2 , Giuseppe Zampogna 2 , Bruno Seriolo 2 and Maurizio Cutolo 1 , 1 Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 2 Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy. 579. Oral N-acetylcysteine in the Treatment of Raynaud’s Phenomenon Secondary to Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Marcelo José Uchoa Correa 2 , Henrique A. Mariz 3 , Luis Eduardo Coelho Andrade 3 and Cristiane Kayser 1 , 1 Universidade Federal de São Palo, Brazil, 2 Universidade Federal de São Paulo, São Paulo, Brazil, 3 Universidade Federal de São Paulo, Brazil. 580. Outcomes of Barrett’s Esophagus Related to Systemic Sclerosis: A 3-Year EULAR/EUSTAR Prospective Follow-Up Study. Julien Wipff 11 , Romain Coriat 9 , Michela Masciocchi 5 , Paola Caramaschi 2 , Chris T. Derk 7 , Eric Hachulla 8 , Valeria Riccieri 12 , Luc Mouthon 10 , Dorota Krasowska 1 , L. P. Ananyeva 6 , Andre Kahan 3 , Marco Matucci-Cerinic 13 , Stanislas Chaussade 9 and Yannick Allanore 4 , 1 Department of Dermatology, Medical University of Lublin, Lublin, 2 Department of Medicine, Verona University, Verona, 3 Hopital Cochin, Paris, France, 4 Hopitaux de Paris Cochin, Paris, France, 5 Immunological Clinic, Mangiagalli Regina Elena Fundation, Milan, 6 Institute of Rheumatology, Russian Academy of Medical Science, Moscow, 7 Jefferson Medical College, Philadelphia, PA, 8 National Scleroderma Centre, Lille Cedex, France, 9 Paris Descartes University, Gastroenterology Dpt, Cochin Hospital, 10 Paris Descartes University, Internal Medicine Dpt, Cochin Hospital, 11 Paris Descartes University, Rheumatology A Dpt, Cochin Hospital, 12 Sapienza University of Rome, Medical Clinic and Therapy Department, Rome, 13 University of Florence, Firenze, Italy. 581. WITHDRAWN 582. Preclinical Evaluation of Cardiac Involvement in Systemic Sclerosis Patients by Speckle Tracking Strain Analysis. Anne A. Schouffoer 3 , Kai H. Yiu 1 , Maarten K. Ninaber 2 , Jan Stolk 2 , Thea P. M. Vliet-Vlieland 3 , Eduard R. Holman 1 , Tom W. J. Huizinga 3 , Jeroen J. Bax 1 , Nina Ajmone Marsan 1 and Annemie J. M. Schuerwegh 4 , 1 Department of Cardiology, Leiden, The Netherlands, 2 Department of Pulmonology, Leiden, The Netherlands, 3 Department of Rheumatology, Leiden, The Netherlands, 4 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. 583. Preliminary Composite Response Index for Raynaud’s Phenomenon. Dinesh Khanna 2 , Paul Maranian 2 , Daniel Furst 2 , James Seibold 3 , Marco Matucci Cerinic 4 , Jeff Gregory 1 and Harold Paulus 2 , 1 MediQuest, 2 UCLA, 3 Univ of Conneticut, 4 Univ of Florence. 584. Prevalence of Coronary Heart Disease in a Cohort of Australian Scleroderma Patients. Gene-Siew Ngian 2 , Joanne Sahhar 7 , Jill Byron 14 , Susanna Proudman 9 , Catherine Hill 8 , Janet Roddy 11 , Peter Youssef 12 , Kathleen Tymms 1 , Leslie Schrieber 10 , Wendy Stevens 14 , Jane Zochling 6 , Peter Nash 15 , Allan Sturgess 13 , Gabor Major 5 , Ian Wicks 3 and Sharon Van Doornum 4 , 1 Canberra Rheumatology, Australia, 2 Department of Medicine (RMH/ WH), University of Melbourne, Melbourne, Victoria, Australia, 3 Department of Medicine (RMH/WH), University of Melbourne, Melbourne, Australia, 4 Department of Medicine (RMH/WH), 2010 Program Book 187
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138: • apply these basic statistics to
Page 139 and 140: 9:15 AM The ACR/EULAR Definition of
Page 141 and 142: Immunology, Oslo University Hospita
Page 143 and 144: 9:15 AM 2239. Factors Associated wi
Page 145 and 146: Upon completion of this session, pa
Page 147 and 148: Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150: Ende 4 , 1 Department of Rheumatolo
Page 151 and 152: ACR Poster Session A Cytokines, Med
Page 153 and 154: ACR Poster Session A 51. Associatio
Page 155 and 156: ACR Poster Session A 83. Respirator
Page 157 and 158: ACR Poster Session A 121. Bone Dens
Page 159 and 160: ACR Poster Session A 142. The Intra
Page 161 and 162: ACR Poster Session A 171. Early Pro
Page 163 and 164: ACR Poster Session A Pediatric Rheu
Page 165 and 166: ACR Poster Session A 233. Prevalenc
Page 167 and 168: ACR Poster Session A 266. Subtype S
Page 169 and 170: ACR Poster Session A 297. Body Weig
Page 171 and 172: ACR Poster Session A 325. Patient R
Page 173 and 174: ACR Poster Session A 356. Influence
Page 175 and 176: ACR Poster Session A 383. Efficacy
Page 177 and 178: ACR Poster Session A 409. Rituximab
Page 179 and 180: ACR Poster Session A 441. Recombina
Page 181 and 182: ACR Poster Session A 465. Immunoglo
Page 183 and 184: ACR Poster Session A 496. IRF8 Alle
Page 185 and 186: ACR Poster Session A 521. DC-STAMP
Page 187: ACR Poster Session A 546. Prevalenc
Page 191 and 192: ACR Poster Session A 599. Validatio
Page 193 and 194: ACR/ARHP Poster Session B Halls B1
Page 195 and 196: ACR Poster Session B 767. Economic
Page 197 and 198: ACR/ARHP Poster Session B 792. The
Page 199 and 200: ACR/ARHP Poster Session B Universit
Page 201 and 202: ACR/ARHP Poster Session B 848. Cell
Page 203 and 204: ACR/ARHP Poster Session B 886. Scre
Page 205 and 206: ACR/ARHP Poster Session B 909. Regu
Page 207 and 208: ACR/ARHP Poster Session B 935. The
Page 209 and 210: ACR/ARHP Poster Session B 967. Frac
Page 211 and 212: ACR Poster Session B 993. Early Exp
Page 213 and 214: ACR/ARHP Poster Session B 1022. Com
Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
Page 217 and 218: ACR Poster Session B 1084. Gene Exp
Page 219 and 220: ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222: ACR Poster Session B hiroshima Memo
Page 223 and 224: ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226: ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228: ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230: ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232: ACR/ARHP Poster Session B 1294. End
Page 233 and 234: ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236: ACR/ARHP Poster Session C Halls B1
Page 237 and 238: ACR/ARHP Poster Session C 1495. S10
Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284:
REF Industry Roundtable-supported S
Page 285 and 286:
REF Industry Roundtable-supported S
Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306:
Cooper, Max D, MD Introduction . .
Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310:
Physical Examination Skills for Imp
Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360:
A α-galactosylceramide 505 A2A kno
Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
Page 363 and 364:
cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?